GV.PA Genomic Vision SA EURONEXT: €0.0018 on 26 Mar 2026, top intraday volume

GV.PA stock opened at €0.0018 on 26 Mar 2026 and is the most active name on EURONEXT by volume today. The share rose 5.88% from the previous close with 38,489,238 shares traded, nearly 2.71x average volume. This intraday surge reflects low market cap liquidity and headline-driven flows rather than changes in company fundamentals.

Intraday snapshot: GV.PA stock trading activity

Today Genomic Vision SA (GV.PA) on EURONEXT is trading between a day low of €0.0015 and a day high of €0.0020, with the last print at €0.0018. Volume hit 38,489,238.00 versus an average volume of 14,217,513.00, giving a relative volume of 2.71. The market cap stands at €693,191.00, reflecting a micro-cap profile and elevated intra-day volatility. High turnover in a low-price stock often amplifies price swings and execution risk for larger orders.

Fundamentals and valuation: GV.PA stock metrics

Genomic Vision reports trailing EPS of -0.11 and a negative PE ratio. Key ratios: Price/Sales 0.47, EV/Sales 1.60, and current ratio 0.91, highlighting tight near-term liquidity. Cash per share is €0.00557 and enterprise value is €2,369,191.00. The company runs a research-heavy model with R&D to revenue around 2.08x, which pressures margins but supports technology assets.

Technical picture and liquidity: GV.PA stock trading

Price averages show a weak trend: 50-day average €0.00484 and 200-day average €0.013997. Year high is €0.0940 and year low €0.00140, indicating a steep decline year-over-year. The stock’s float and low market cap cause thin order book depth. Short-term traders should expect wide spreads, and larger investors face significant market impact.

Catalysts and news: GV.PA stock update

Recent coverage in broader healthcare outlets highlights sector activity rather than company-specific releases. For background on healthcare trends see Reuters healthcare coverage and a sector conference transcript on Seeking Alpha. These sources provide context for diagnostic names like Genomic Vision and possible demand shifts for molecular tools. For company information visit the official site or our Meyka stock page for GV.PA.

Meyka grade and forecast: GV.PA stock outlook

Meyka AI rates GV.PA with a score out of 100: 62.43 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month central price of €0.00500, implying an upside of 177.78% from €0.0018. Forecasts are model-based projections and not guarantees. Investors should weigh the forecast against tight liquidity, prolonged negative EPS, and sector headwinds.

Final Thoughts

GV.PA stock is an intraday standout on EURONEXT due to its €0.0018 price and heavy 38,489,238.00 share turnover on 26 Mar 2026. The micro-cap structure produces outsized moves on modest order flow, so volume spikes today reflect liquidity-driven trading rather than a clear shift in fundamentals. Financials show negative earnings (EPS -0.11), a low current ratio (0.91), and negative operating cash flow per share (€-0.03232), which underline ongoing funding risk for operations. Sector-wise, healthcare momentum is mixed YTD and dialogs in diagnostics affect demand for Genomic Vision’s FiberVision and combing systems. Meyka AI’s model projects a 12-month target of €0.00500, an implied upside of 177.78% from the current price; this projection is speculative and model-driven. Our view frames GV.PA as a high-risk, high-volatility speculative trade suited to liquidity-tolerant traders or those adding a small allocation for asymmetric upside, while larger investors should limit position size and use limit orders to manage market impact. For real-time updates, see the Meyka AI stock page for GV.PA and follow credible sector news.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.